X
XORTX Therapeutics Inc. (XRTX)
NCM – Real vaqt narxi. Valyuta: USD
2.19
+0.03 (1.44%)
Yopilishda: Jun 26, 2026, 4:00 PM EDT
2.20
+0.01 (0.38%)
Bozordan keyin: Jun 26, 2026, 6:53 PM EDT
Aksiya tahlili uchun eng kuchli vositalarga ega bo'ling
Find any stock by ticker or company name
NCM – Real vaqt narxi. Valyuta: USD
2.19
+0.03 (1.44%)
Yopilishda: Jun 26, 2026, 4:00 PM EDT
2.20
+0.01 (0.38%)
Bozordan keyin: Jun 26, 2026, 6:53 PM EDT
XORTX Therapeutics Inc., kechki bosqichdagi klinik farmatsevtika kompaniyasi, Kanadada giperurikemiya bilan bog'liq kasalliklarni davolash uchun terapiyalarni ishlab chiqish va tijoratlashtirish bilan shug'ullanadi. Kompaniya podagrani davolash uchun III bosqichda bo'lgan XRx-026; autosomal dominant polikistik buyrak kasalligini davolash uchun II bosqichda bo'lgan XRx-008; sepsis va koronavirus, shu jumladan respirator virusli infektsiya bilan bog'liq o'tkir buyrak shikastlanishini davolash uchun II bosqichda bo'lgan XRx-101; va 2-toifa diabetik nefropatiyani davolash uchun preklinik bosqichda bo'lgan XRX-225, shuningdek, buyrakdagi fibrozni davolash va oldini olish dasturi bo'lgan VB4-P5 ni ishlab chiqadi. Kompaniya Kalgarida, Kanadada joylashgan.
| Ism | Lavozim |
|---|---|
| Dr. Michael Scott Bumby D.V.M., M.B.A. | Chief Financial Officer |
| Dr. Stacy Evans M.B.A., M.D. | Chief Business Officer |
| Dr. Stephen Haworth M.D., MRCP | Chief Medical Officer |
| Sana | Turi | Hujjat |
|---|---|---|
| 2026-06-15 | 6-K | f6k_061526.htm |
| 2026-06-12 | 6-K | f6k_061226.htm |
| 2026-05-19 | 6-K | f6k_051826.htm |
| 2026-05-14 | 6-K | f6k_051426.htm |
| 2026-05-08 | POS AM | tm265452-8_posam.htm |
| 2026-05-08 | 6-K | tm265452d11_6k.htm |
| 2026-04-23 | POS AM | tm265452-6_posam.htm |
| 2026-04-22 | POS AM | tm265452-4_posam.htm |
| 2026-04-21 | 6-K | f6k_042126.htm |
| 2026-04-16 | 6-K | f6k_041626.htm |